Previous close | 143.03 |
Open | 144.00 |
Bid | 139.51 x 100 |
Ask | 139.86 x 300 |
Day's range | 139.64 - 144.09 |
52-week range | 89.04 - 148.37 |
Volume | |
Avg. volume | 908,477 |
Market cap | 14.064B |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | 56.61 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 29 Dec 1995 |
1y target est | N/A |
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc